HLS Therapeutics, Inc. HLS

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS) announces the appointment of Linda Maxwell, M.D. and Mark DeLong as independent directors to its Board of Directors (the "Board"), effective today. The appointments follow the departures of Dr. Kyle Dempsey and Christine Elliott. Following these changes, the Board comprises eight directors, six of whom are independent.

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announced today that it has filed with the Toronto Stock Exchange (the "TSX"), and the TSX has accepted, an amended notice of intention regarding its existing normal course issuer bid (the "NCIB") to increase the number of common shares (each a "Common Share") that may be repurchased for cancellation from 1,500,000 to 1,872,685 Common Shares, representing approximately 10% of the public float as of June 12, 2026, the maximum amount allow

Price targets on HLS Therapeutics have widened, with the most optimistic research pointing to C$8 while more cautious views sit near C$5. This spread reflects the recent shift in analyst commentary, where some see an inflection point for growth and cash generation, while others prefer to wait for more proof in upcoming quarters. As you read on, you will see what is driving these views and how to track the evolving story around HLS Therapeutics. Stay updated as the Fair Value for HLS...

Strong Naleo uptake and Vascepa growth drive robust performance, offset by launch-related investments impacting near-term margins

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release financial results for the three and six months ended June 30, 2026, on Wednesday, August 12, 2026. The Company will hold a conference call that same day at 10:00 a.m. ET to discuss its results. The call will be hosted by Craig Millian, Chief Executive Officer; John Hanna, Chief Financial Officer; and Brian Walsh, Chief Commercial Officer. Slides to accompany management's prepared remarks will be available v

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 26, 2026.

HLS Therapeutics (TSE:HLS) reported modest first-quarter revenue growth and reaffirmed its 2026 outlook, while management highlighted early momentum for the company’s newly launched cholesterol drug NILEMDO and continued deleveraging of its balance sheet. On a conference call discussing results for

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three months ended March 31, 2026 ("Q1 2026"). All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.

HLS Therapeutics Inc. ( TSE:HLS ) is possibly approaching a major achievement in its business, so we would like to...

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, today announced the commercial launch of NILEMDO™ (bempedoic acid) in Canada. NILEMDO is now available by prescription nationally. HLS in-licensed the exclusive rights to NILEMDO and NEXLIZET® (bempedoic acid and ezetimibe) for the Canadian market from Esperion Therapeutics Inc. ("Esperion") (NASDAQ: ESPR) in M